NicOx.... in attesa di.....

[elfrancese]

je rajouterai que le bimatoprost (base molaire de NCX470) > latanoprost (base molaire de vyzulta)

la prouesse de Nicox aura été d'abaisser les effets indésirables avec l'optimisation de la molécule avec le NO, le bimatoprost c'est plus de 40% d'AES. nicox doit viser moins de 20 je pense

comme viralic, je n'ai aucun doute sur la phase clinique...le dosage choisi l'amènera au niveau du rocklatan si l'on suit la logique vu en phase 2 avec effet plateau des AES... la seule serait l'étape d'enregistrement, ainsi j'aimerais que l'américanisation soit actée après la phase 3 mont blanc pour préparer le dossier avec la fda

j'aimerais aussi que Nicox n'oublie pas l'Europe , ou attend t'elle d'aprehenser la possibilité" d'un rachat par un major qui voudrait avoir le champ libre pour l'Europe ?

 

[PIZZODIGINO]

Ennesima giornata negativa. Certo che l'andamento del titolo è deprimente.

 

[elfrancese]

oui pizzo dans des volumes ridicules...
comme si 2M$ ne valaient rien quand il s'agit de nicox

 

[viralic]

Ennesima giornata negativa. Certo che l'andamento del titolo è deprimente.
[/CITAZIONE]

preciserei...ennesima giornata negativa per le bio europee... specie quelle francesi.

 

[elfrancese]

exact, qu'est ce qui ne va pas sur notre biotech ??? à comparer avec les anglaises, nordiques, ou belge hollandaise ?

quand on voit poxel après une amm japon... moins de 200M, quelle tristesse

et de l'autre coté argenx... qui n'a pas sorti la pilule pour rester éternel... qui valorise 13 milliards soit 2 fois ce que valorise les 30 biotechs françaises !!! et dans tout ca, y a quand meme, NICOX et ses NCX, viaskin de dbv, fibrastat de quantum, imeglebine de poxel, masitinib d'ab, les vaccins de transgene, les traitements innovants et prometteur de nanobiotix, les vaccins de valneva.... quand le gouvernement va nous sortir un plan ambitieux avec les banques, business angel, attractivité a investir sur les bio en bourse ??

 

[elfrancese]

forza Italia !!!!

 

[elcucador]

forza Italia !!!!

Merci.

 

[elfrancese]

Vyzulta est un bon médicament ! Un médicament nécessaire ! Il est possible qu'a un moment ou l'on ne s'y attendra plus, cela prenne sens chez les prescripteurs !

ARVO Annual Meeting Abstract | June 2021
Adjunctive use of latanoprostene bunod in refractory glaucoma: 1-year retrospective analysis
Christine J Ha; Vladislav Bekerman; Benjamin Zhou; Reshma Vohra; Albert S Khouri
Author Affiliations & Notes

Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2762. doi:


Abstract
Purpose : Latanoprostene bunod is a new medication whose main additional mechanism is nitric oxide donation. Its downstream effect improves trabecular meshwork outflow. Published studies have proven its efficacy alone as primary therapy in treatment-naïve eyes. This study retrospectively investigated the long-term efficacy of adjunctive use of latanoprostene bunod in refractory cases of glaucoma at a tertiary care glaucoma clinic. Refractory cases were judged as requiring ≥3 topical medications.
Methods : Retrospective chart review for patients on ≥3 topical medications who received add-on latanoprostene bunod was conducted from 01/01/2018 to 08/31/2020. Patients’ baseline characteristics prior to add-on therapy were recorded and included type of glaucoma and prior topical, laser, and surgical treatments. A baseline IOP was calculated by taking the average of the two most recent IOP measurements prior to latanoprostene bunod add-on treatment. IOP was measured at 3-, 6-, and 12-month intervals ±4 weeks. A Bonferroni corrected student’s T-test was used to test differences between groups with statistical significance set at p = 0.01.
Results : 53 eyes in 36 patients were included in this analysis. Mean age (±SD) was 72.1±11.0. 18 (50%) patients were Caucasian, 13 (36%) African American, 2 (5%) Hispanic, 2 (5%) Indian American, and 1 (2%) Asian. Glaucoma diagnoses were as follows: 45 (85%) primary open angle, 6 (11%) neovascular, and 2 (4%) uveitic. Prior surgeries included: 11 (21%) trabeculoplasty, 9 (17%) seton, 2 (4%) trabeculectomy, and 2 (4%) iStent (Table 1). Mean IOP mmHg (±SD) at baseline was 19.9±6.0. Follow-up mean IOP mmHg (±SD) are as follows: 3-month 17.3±5.5 (p<0.01) in 49 eyes, 6-month 17.2±6.6 (p<0.01) in 35 eyes, and 12-month 16.1±4.5 (p<0.01) in 28 eyes (Table 2).
Conclusions : Adjunctive use of latanoprostene bunod in refractory glaucoma showed clinically and statistically significant IOP reductions. This study suggests that adding latanoprostene bunod to eyes with previous medical or surgical treatment can provide longer term IOP reduction. Further analysis is required to fully understand the effect of latanoprostene bunod in refractory glaucoma.
This is a 2021 ARVO Annual Meeting abstract.

 

[elcucador]

Si certo una
Volta sono le bio europee,poi quelle francesi,poi il NASDAQ,poi il cac,poi il covid e i ritardi,poi gli shorter etc etc
Ma strano che poi quando tutto avviene al contrario nicox rimane al palo o fa rialzi insignificanti
Abbiate il coraggio di dire
Che e'un titolo o alla mercé di qualsiasi stronzate avviene visto che poi ha avuto anche una serie di notizie che la dovevano almeno sostenere invece affonda come tutte anzi peggio delle altre
Altro che grande titolo da grandi fatturati e grandi target.
È solo un titolo seguito da pochi e di scarso appeal.

 

[elfrancese]

390k pour aller à 3,83 et 90 k pour revenir au point de départ...

on est d'accord, tout est normal...